|
Press Releases |
|
|
|
Friday, August 25, 2023 |
|
华领医药公布2023年中期业绩 |
-- 全球首创新药葡萄糖激酶激活剂(GKA)多格列艾汀(商品名:华堂宁®)于2022年9月在中国获批上市。 more info >> |
|
華領醫藥公佈2023年中期業績 |
-- 全球首創新藥葡萄糖激酶激活劑(GKA)多格列艾汀(商品名:華堂寧®)於2022年9月在中國獲批上市。 more info >> |
|
Hua Medicine Announces 2023 Interim Results |
First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
Monday, October 10, 2022 |
|
华领医药全球首创新药葡萄糖激酶激活剂华堂宁(R)获批上市 有望拓展中国2型糖尿病治疗新格局 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,公司研发的全球首创(first-in-class)新药葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片,dorzagliatin,HMS5552)已于10月8日获得中国国家药品监督管理局(NMPA)的上市批准。 more info >> |
|
華領醫藥全球首創新藥葡萄糖激酶激活劑華堂寧(R)獲批上市 有望拓展中國2型糖尿病治療新格局 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK)今天宣佈,公司研發的全球首創(first-in-class)新藥葡萄糖激酶激活劑(GKA)華堂寧®(多格列艾汀片,dorzagliatin,HMS5552)已於10月8日獲得中國國家藥品監督管理局(NMPA)的上市批准。 more info >> |
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
Tuesday, June 7, 2022 |
|
华领医药在2022ADA科学年会公布多格列艾汀能够明显改善2型糖尿病患者和GCK-MODY患者的胰岛素早相分泌和葡萄糖敏感性 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,在第82届美国糖尿病协会(ADA)科学年会上,公司展示了其全球首创新药葡萄糖激酶激活剂(GKA)多格列艾汀(dorzagliatin)的多项临床研究成果。 more info >> |
|
華領醫藥在2022ADA科學年會公佈多格列艾汀能夠明顯改善2型糖尿病患者和GCK-MODY患者的胰島素早相分泌和葡萄糖敏感性 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK)今天宣佈,在第82屆美國糖尿病協會(ADA)科學年會上,公司展示了其全球首創新藥葡萄糖激酶啟動劑(GKA)多格列艾汀(dorzagliatin)的多項臨床研究成果。 more info >> |
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
Friday, May 13, 2022 |
|
祝贺!国际顶级医学期刊《自然-医学》同时发表两篇关于华领医药全球首创糖尿病新药多格列艾汀的III期研究结果的同行评议论文 |
华领医药(“公司”,香港联交所主板股份代号:2552.HK)今日宣布,国际顶级医学刊物《自然-医学》(Nature Medicine)杂志同时在线发表了两篇公司全球首创糖尿病新药葡萄糖激酶激活剂(GKA)多格列艾汀(dorzagliatin)的III期注册临床研究结果的同行评议论文。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Rover Announces and Closes $0.03 Unit Financing
May 16, 2024 05:00 HKT/SGT
|
|
|
New Research Increases Confidence in the Benefits of Vegan Diets for Dogs
May 16, 2024 05:00 HKT/SGT
|
|
|
3rd Annual Clean Power & New Energy 2024
May 15, 2024 21:53 HKT/SGT
|
|
|
Dubai FinTech Summit concludes with over 8,000 visitors from 118 countries
May 15, 2024 21:40 HKT/SGT
|
|
|
思捷环球重组德国业务 降本增效启航新征程
May 15, 2024 18:47 HKT/SGT
|
|
|
思捷環球重組德國業務 降本增效啟航新征程
May 15, 2024 18:44 HKT/SGT
|
|
|
曹操出行好司機張桂容獲得2024全國五一勞動獎章
May 15, 2024 18:00 HKT/SGT
|
|
|
Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles
May 15, 2024 14:30 JST
|
|
|
Intermodal Terminal Company (ITC) Chooses Hexagon to Deliver Groundbreaking Australian Rail Terminal
May 15, 2024 12:32 HKT/SGT
|
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
May 15, 2024 11:19 JST
|
|
|
Honda、将来のSDV実現に向け、IBMと次世代半導体・ソフトウェア技術の長期共同研究開発に関する覚書を締結
May 15, 2024 10:00: JST
|
|
|
Five Tips to build Personalised Engagement with your Customers
May 15, 2024 09:05 HKT/SGT
|
|
|
Former Microsoft, IBM and Compaq Executive to Head APJ Expansion for GTDC
May 15, 2024 09:00 HKT/SGT
|
|
|
上海机电拟收购上海集优 利好催化构建双轮驱动发展格局
May 14, 2024 21:01 HKT/SGT
|
|
|
上海機電擬收購上海集優 利好催化構建雙輪驅動發展格局
May 14, 2024 20:59 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|